ശ്വാസകോശ അർബുദം
First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
എവിടേക്ക് പോകണം
ഈ ട്രയലിനായി ഇന്ത്യയിൽ 6 ആശുപത്രികൾ രോഗികളെ എടുക്കുന്നുണ്ട്.
രജിസ്ട്രി സംഗ്രഹം (technical)
This is a phase 1, multicentre, first-in-human, open-label, dose-escalation/consolidation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered JBI-778 in EGFR mutated lung cancer patients with or without brain metastasis, IDH mutated WHO grade 3 /4 recurrent glioma and ACC with evidence of recurrent, metastatic or advanced, incurable disease arising from any primary site. A total of 42 patients will be recruited in the study. The initial dose escalation up to cohort 3 (estimate to be 160mg) or until the pharmacologically active dose …
Sponsor: Jubilant Therapeutics India Limited
NCT07755397 on ClinicalTrials.gov · CTRI number CTRI/2024/07/070802
Last updated on the registry 10 Aug 2026 · read by us 20 Oct 2026